Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ethical Dilemmas II01:30

Ethical Dilemmas II

840
Resolving an ethical dilemma in healthcare involves a systematic approach that considers every aspect of the issue, respecting both the patient's needs and values and the healthcare professional's ethical obligations. Here are potential steps to resolve an ethical dilemma:
840
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

997
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
997
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
Levels of Health Promotion and Illness Prevention01:26

Levels of Health Promotion and Illness Prevention

11.2K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
11.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

545
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
545

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Ischemic Postconditioning in Patients With Acute Stroke With Successful Recanalization After Endovascular Therapy: A Pilot Randomized Controlled Trial.

Stroke·2026
Same author

RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known Well.

Stroke (Hoboken, N.J.)·2026
Same author

Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke.

Stroke·2025
Same author

The Large Core Paradox.

Stroke·2025
Same author

Statement of Support for the FDA.

Stroke·2025
Same author

Comparative Effectiveness of Conservative Management Versus Surgical Fixation in Acute Type II Odontoid Fractures.

Neurosurgery·2025

Related Experiment Video

Updated: May 10, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.7K

Dilemmas in Secondary Stroke Prevention.

Stephanie Vu1, Noor Mahmoud1, Shravan Sivakumar1

  • 1Department of Neurology (S.V., N.M., S.S., M.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Stroke
|April 21, 2025
PubMed
Summary

This review examines secondary stroke prevention strategies, focusing on antithrombotic therapy and risk factor management when clinical trial data is limited. It addresses complex scenarios like dual-antiplatelet therapy and statin use.

Keywords:
anticoagulantscerebral infarctionfibrinolytic agentsischemic attack, transientplatelet aggregation

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

11.8K
Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
09:52

Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide

Published on: January 15, 2017

17.1K

Related Experiment Videos

Last Updated: May 10, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.7K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

11.8K
Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
09:52

Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide

Published on: January 15, 2017

17.1K

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Secondary stroke prevention involves multiple strategies, including antithrombotic therapy and lifestyle changes.
  • Clinical trial evidence guides recommendations, but some treatment decisions involve extrapolation or insufficient data.

Purpose of the Study:

  • To review complex scenarios in secondary stroke prevention where clinical trial evidence may be limited or require interpretation.
  • To discuss four specific clinical situations: dual-antiplatelet therapy, combined antiplatelet and anticoagulation risks, statin indications, and paroxysmal atrial fibrillation management.

Main Methods:

  • Literature review and synthesis of existing clinical trial data and expert guidelines.
  • Discussion of four distinct clinical scenarios requiring nuanced decision-making.

Main Results:

  • Dual-antiplatelet therapy requires careful consideration of bleeding risk versus thrombotic risk.
  • Combining antiplatelet and anticoagulation significantly increases hemorrhage risk.
  • Statin therapy is indicated for secondary stroke prevention based on established guidelines.
  • Therapeutic strategies for paroxysmal atrial fibrillation aim to reduce embolic stroke risk.

Conclusions:

  • Evidence-based recommendations are crucial, but clinical judgment is essential in complex secondary stroke prevention cases.
  • Optimizing antithrombotic therapy and managing risk factors are key to reducing recurrent stroke.
  • Further research may be needed to clarify optimal management in specific patient populations.